Relatlimab and nivolumab in the treatment of melanoma

Article Oncology

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

Jedd D. Wolchok et al.

Summary: The 6.5-year results of the CheckMate 067 trial demonstrate durable clinical benefits with nivolumab plus ipilimumab or nivolumab monotherapy compared to ipilimumab alone in patients with advanced melanoma.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma

Hussein A. Tawbi et al.

Summary: LAG-3 and PD-1 are two distinct inhibitory immune checkpoints that contribute to T-cell exhaustion. The combination of relatlimab and nivolumab has been shown to be safe and effective in previously treated melanoma patients, and this study aimed to evaluate its safety and activity in previously untreated melanoma patients. The results demonstrated that the combination therapy provided a greater benefit in terms of progression-free survival compared to nivolumab alone, without any new safety signals.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Neoadjuvant relatlimab and nivolumab in resectable melanoma

Rodabe N. Amaria et al.

Summary: The combination of Relatlimab and nivolumab improves progression-free survival and has a high pathologic complete response rate in patients with advanced melanoma. This new immunotherapy regimen shows favorable safety compared to other combination immunotherapy regimens.

NATURE (2022)

添加到收藏夹

Article Oncology

Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma

Lewis Au et al.

Summary: The ADAPTeR study aimed to investigate the mechanism of therapeutic response to nivolumab in metastatic clear cell renal cell carcinoma, with genomic analysis showing no correlation between tumor molecular features and response. Pre-existing immunity may play a key role in predicting clinical response.

CANCER CELL (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Understanding and treating the inflammatory adverse events of cancer immunotherapy

Michael Dougan et al.

Summary: Immunotherapies have had a significant impact on cancer treatment over the past decade, but inflammatory toxicities remain a major concern for certain therapies. Understanding the balance between pro- and anti-inflammatory pathways is crucial for limiting inflammatory toxicities while preserving anti-tumor efficacy.

CELL (2021)

添加到收藏夹

Article Oncology

Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study

Hussein A. Tawbi et al.

Summary: The study demonstrated the durable response, overall survival, and progression-free survival rates for asymptomatic patients treated with nivolumab plus ipilimumab. In contrast, the efficacy was lower in symptomatic patients. Treatment-related adverse events were mainly mild to moderate.

LANCET ONCOLOGY (2021)

添加到收藏夹

Review Oncology